Calendar | For Your Patients | PHA Main Site | Contact Us | About Us | Not a registered user? Sign up here.

Courses Quicksearch

Search Now!

Courses

Understanding Pulmonary Hypertension: From the Micro Level to the Global Impact

Ghazwan Butrous


Sebastien Bonnet

Mourad Toporsian

0 comments
Leave a Comment

Course ID: 2220

The Global Spectrum of Pulmonary Hypertension and its Forgotten Impact on the Developing World

Ghazwan Butrous, MB, ChB, PhD
Managing Director
Pulmonary Vascular Research Institute
Canterbury, United Kingdom

Learning Objectives

  1. Discuss the scope of the pulmonary vascular diseases worldwide and in particular the developing world.
  2. Evaluate the difference in the presentation and management of pulmonary vascular diseases between the developed and developing world.
  3. Discuss the steps to increase awareness and the international collaboration to support patients in the developing world with pulmonary hypertension.

Understanding the Molecular Origin of Pulmonary Hypertension: Role of MicroRNAs

Sebastien Bonnet, PhD
Associate Professor of Medicine
Laval University
Quebec City, Canada

Learning Objectives

  1. Describe the mechanism of pulmonary artery remodeling 
  2. Describe the underlying disorders of miR-204 down regulation in PAH
  3. Discuss the putative role of miRNA in PAH treatment

Pathogenesis of Pulmonary Arterial Hypertension: Clues from the Animal Models of Hereditary Hemorrhagic Telangiectasia

Mourad Toporsian, PhD
Instructor in Medicine
Harvard Medical School
Beth Israel Deaconess Medical Center
Boston, Mass.

Learning Objectives

  1. Describe the clinical signs and symptoms of Hereditary Hemorrhagic Telangiectasia (HHT) and the genes mutated in this disease
  2. Recall that some HHT patients can present with PAH and define how HHT and PAH share common defects in genes and signaling pathways
  3. Discuss how changes in Endoglin and ALK-1-dependent cell signaling can spontaneously cause PAH in mice
  4. Discuss potential therapeutic targets in the treatment of PAH

Release Date

29 May 2013

Expiration Date

29 May 2015 

Accreditation and Credit Designation

This activity has been planned and implemented in accordance with the essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of ProCE, Inc., the National Association of Managed Care Physicians (NAMCP), and the Pulmonary Hypertension Association (PHA). The NAMCP is accredited by the ACCME to provide continuing medical education (CME) to physicians. The NAMCP designates this enduring material for a maximum of 3.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Instructions for Earning Credit

This activity is a self-study program. Upon entering the activity, participants should read the text, examine any images and/or multimedia features, and review the content presented within all of the links provided. Once the course has been reviewed in its entirety, participants will be asked to complete a post-test and evaluation online. Participants must receive a test score of 100% in order to proceed to the course evaluation; the post-test can be repeated until all questions are answered correctly. All evaluation questions must be completed in order to receive a certificate of credit. If needed, participants may save their answers and complete the course at a later date. Saved courses can be found on the "My Activities" page, accessed via "My Account" at the top of the page.

Faculty Disclosures

It is the policy of ProCE to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer of any commercial product(s) discussed in an educational presentation.

Ghazwan Butrous, MB, ChB, PhD, indicates that he has served as a consultant or as part of a speaker bureau for Novartis and Bayer and is a stock shareholder with Pfizer.

Mourad Toporsian, PhD, indicates that he has no significant financial interest or any other relationship to disclose.

Sebastien Bonnet, PhD, indicates that he has no significant financial interest or any other relationship to disclose.

Disclaimer

The opinions expressed in this program should not be construed as those of the CE provider. The information and views are those of the faculty through clinical practice and knowledge of the professional literature. Portions of this program may include the use of drugs for unlabeled indications. Use of drugs outside of labeling should be considered experimental and participants are advised to consult prescribing information and professional literature.

No portion of this activity may be reproduced without the expressed written consent of PHA.

Estimated Time to Complete This Activity

3 hours

Privacy Policy

For information about the PHA's privacy policy, visit http://www.phassociation.org/privacy.asp.

This activity is made possible through unrestricted educational grants from Actelion, Gilead, United Therapeutics and Bayer.

©2013 Pulmonary Hypertension Association, 801 Roeder Road, Suite 1000, Silver Spring, MD 21910.